These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Effects of Chronologic Age and Young Child Exposure on Respiratory Syncytial Virus Disease among US Preterm Infants Born at 32 to 35 Weeks Gestation. Simões EA; Anderson EJ; Wu X; Ambrose CS PLoS One; 2016; 11(11):e0166226. PubMed ID: 27898687 [TBL] [Abstract][Full Text] [Related]
24. Risk factors for hospitalisation due to respiratory syncytial virus infection in children receiving prophylactic palivizumab. Chida-Nagai A; Sato H; Sato I; Shiraishi M; Sasaki D; Izumi G; Yamazawa H; Cho K; Manabe A; Takeda A Eur J Pediatr; 2022 Feb; 181(2):539-547. PubMed ID: 34417646 [TBL] [Abstract][Full Text] [Related]
25. Detection of respiratory syncytial virus A and B and parainfluenzavirus 3 sequences in respiratory tracts of infants by a single PCR with primers targeted to the L-polymerase gene and differential hybridization. Eugene-Ruellan G; Freymuth F; Bahloul C; Badrane H; Vabret A; Tordo N J Clin Microbiol; 1998 Mar; 36(3):796-801. PubMed ID: 9508315 [TBL] [Abstract][Full Text] [Related]
26. Prophylaxis for respiratory syncytial virus with respiratory syncytial virus-immunoglobulin intravenous among preterm infants of thirty-two weeks gestation and less: reduction in incidence, severity of illness and cost. Atkins JT; Karimi P; Morris BH; McDavid G; Shim S Pediatr Infect Dis J; 2000 Feb; 19(2):138-43. PubMed ID: 10694001 [TBL] [Abstract][Full Text] [Related]
27. Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Respiratory Syncytial Virus Immune Globulin Study Group. Groothuis JR; Simoes EA; Hemming VG Pediatrics; 1995 Apr; 95(4):463-7. PubMed ID: 7700741 [TBL] [Abstract][Full Text] [Related]
28. Severe Respiratory Syncytial Virus Infection in Preterm Infants and Later Onset of Asthma. Jalink MB; Langley JM; Dodds L; Andreou P Pediatr Infect Dis J; 2019 Nov; 38(11):1121-1125. PubMed ID: 31425330 [TBL] [Abstract][Full Text] [Related]
29. Identification of potential immune/diagnosis related gene-immunocyte subtype networks in extracellular immune response to respiratory syncytial virus infection. Wang B; Liu H Virus Res; 2022 Nov; 321():198906. PubMed ID: 36044931 [TBL] [Abstract][Full Text] [Related]
30. Immune Profiling of Cord Blood From Preterm and Term Infants Reveals Distinct Differences in Pro-Inflammatory Responses. Anderson J; Thang CM; Thanh LQ; Dai VTT; Phan VT; Nhu BTH; Trang DNX; Trinh PTP; Nguyen TV; Toan NT; Harpur CM; Mulholland K; Pellicci DG; Do LAH; Licciardi PV Front Immunol; 2021; 12():777927. PubMed ID: 34790206 [TBL] [Abstract][Full Text] [Related]
31. Respiratory syncytial virus risk factors in late preterm infants. Lanari M; Silvestri M; Rossi GA J Matern Fetal Neonatal Med; 2009; 22 Suppl 3():102-7. PubMed ID: 19925369 [TBL] [Abstract][Full Text] [Related]
32. Predictors and incidence of hospitalization due to respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) in non-prophylaxed moderate-to-late preterm infants in Bosnia and Herzegovina. Maksić H; Heljić S; Skokić F; Šumanović-Glamuzina D; Milošević V; Zlatanović A; Gerard N Bosn J Basic Med Sci; 2018 Aug; 18(3):279-288. PubMed ID: 29750895 [TBL] [Abstract][Full Text] [Related]
33. Molecular characterization of respiratory syncytial viruses circulating in a paediatric cohort in Amman, Jordan. Trovão NS; Khuri-Bulos N; Tan Y; Puri V; Shilts MH; Halpin RA; Fedorova NB; Nelson MI; Halasa N; Das SR Microb Genom; 2021 Jun; 7(6):. PubMed ID: 31532357 [TBL] [Abstract][Full Text] [Related]
34. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial. Man WH; Scheltema NM; Clerc M; van Houten MA; Nibbelke EE; Achten NB; Arp K; Sanders EAM; Bont LJ; Bogaert D Lancet Respir Med; 2020 Oct; 8(10):1022-1031. PubMed ID: 32203712 [TBL] [Abstract][Full Text] [Related]
35. A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29-35 weeks' gestational age. Keary IP; Ravasio R; Fullarton JR; Manzoni P; Lanari M; Paes BA; Carbonell-Estrany X; Baraldi E; Tarride JÉ; Rodgers-Gray B PLoS One; 2023; 18(8):e0289828. PubMed ID: 37561741 [TBL] [Abstract][Full Text] [Related]
36. Neutrophil TLR4 expression is reduced in the airways of infants with severe bronchiolitis. Halfhide CP; Brearey SP; Flanagan BF; Hunt JA; Howarth D; Cummerson J; Edwards S; Hart CA; Smyth RL Thorax; 2009 Sep; 64(9):798-805. PubMed ID: 19497921 [TBL] [Abstract][Full Text] [Related]
39. SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis. Anderson EJ; DeVincenzo JP; Simões EAF; Krilov LR; Forbes ML; Pannaraj PS; Espinosa CM; Welliver RC; Wolkoff LI; Yogev R; Checchia PA; Domachowske JB; Halasa N; McBride SJ; Kumar VR; McLaurin KK; Rizzo CP; Ambrose CS Am J Perinatol; 2020 Mar; 37(4):421-429. PubMed ID: 30991438 [TBL] [Abstract][Full Text] [Related]
40. Impact of the 2014 American Academy of Pediatrics Immunoprophylaxis Policy on the Rate, Severity, and Cost of Respiratory Syncytial Virus Hospitalizations among Preterm Infants. Krilov LR; Fergie J; Goldstein M; Brannman L Am J Perinatol; 2020 Jan; 37(2):174-183. PubMed ID: 31430818 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]